

Lord of the RINs

The Fellowship of the EPA can provide policy relief while US Congress debates a permanent legislative solution for RFS2...

- **Skyrocketing Renewable Identification Number (RIN) prices and the gasoline “blend wall” have once again come to the fore this year.** The core of the issue remains a policy bind deriving from the 2007 Renewable Fuel Standard (RFS2) enforced by the Environmental Protection Agency (EPA). The bipartisan law requires obligated parties (OP)—domestic refiners and importers—to blend growing volumes of ethanol and other alternative fuels into the final US gasoline and diesel supply. But mandated volumes are clashing with a structural decline in domestic demand for motor gasoline, thus making RFS2 compliance physically onerous and eventually unfeasible. Excess blending from prior years created ‘paper’ RIN credits that can be drawn down, but are now drying up. Prices for credits have surged ten-fold this year and are likely to push much higher in 2014 absent policy relief as RFS2 becomes even more binding.
- **While we expect no major policy shift from the EPA for its forthcoming final 2013 rule that might publish later this month, the agency will be pressed to address the more binding RFS2 mandates for 2014 and beyond.** Absent policy relaxation RFS2 becomes unsustainable by 2015. While the US Congress could take immediate steps to fix the program, politics remain divisive. Unless high RIN prices lead to a sustained increase in retail gasoline prices, we would not anticipate Congressional action prior to 2014. The EPA has some flexibility to alter rules as administrator of the program via annual waivers but timing is critical. A permanent solution would require Congressional action, but EPA can provide the much needed breathing room.
- **Various policy and market options under consideration for 2014/2015 include:** (1) Holding the 2013 RFS2 proposed volumes constant to 2014 and until ethanol demand expands. This can also involve reducing the advanced biofuels carve-out on both a constituency and aggregate basis. (2) Producing more E15 / E85 and thereby pushing out the blend wall. But this is slow and difficult to implement given current vehicle fleets, a dearth of filling stations and consumer preferences that do not favor large-scale use of midlevel blends. (3) Adjusting the biodiesel (D4) market in ethanol equivalent (EE) terms from 1.5x to 2x or higher—an accounting metric that could reduce RIN generation costs (which ultimately underpins the dilemma with RFS2 for future years due to the lack of low-cost RIN generation capacity given the blend wall).
- **To be sure, the EPA is likely comfortable with high RIN prices persisting.** In theory this should encourage higher level blends—a stated agency policy objective. In practical terms it promotes the drawdown of D6 and advanced RINs—of which there are only sufficient quantities for compliance in the near term and could run out in 2014. **Any RFS2 policy easing—even if it were to be implemented or adjusted as far out as 2015—should be bearish RIN prices;** improving the prospects for both RIN carryout y/y (at the 20% cap) as well as new generation, in a less binding environment.

- Commodities
- Regulations

Aakash Doshi
+1-212-723-3872
aakash.doshi@citi.com

Eric G Lee
+1-212-723-1474
eric.g.lee@citi.com

Seth M Kleinman
+44-20-7986-7084
seth.kleinman@citi.com

Edward L Morse
+1-212-723-3871
ed.morse@citi.com


Anthony Yuen
+1-212-723-1477
anthony.yuen@citi.com

Christopher J Main
chris.main@citi.com

Xing Xing
xing.xing@citi.com

With thanks to
Richard Morse

Figure 1. Underlying Commodity Prices



Source: Bloomberg, Citi Research

See Appendix A-1 for Analyst Certification, Important Disclosures and non-US research analyst disclosures.

Citi Research is a division of Citigroup Global Markets Inc. (the “Firm”), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

The Fellowship at the EPA should provide policy relief sooner rather than later¹...

Figure 2. Renewable Fuel Standards from the 2007 Energy Legislation (EISA) or RFS2*

bn-gal	Corn Based Ethanol	Advanced Renewables	Sum
2011	12.6	1.4	14
2012	13.2	2	15.2
2013	13.8	2.8	16.6
2014	14.4	3.8	18.2
2015	15	5.5	20.5
2016	15	7.3	22.3
2017	15	9	24
2018	15	11	26
2019	15	13	28
2020	15	15	30
2021	15	18	33
2022	15	21	36

Source: EPA, Citi Research, *rounded to nearest single decimal point


Figure 3. Estimated RIN Carryover (2013)

Type	bn-gal
D6 Conventional	2.1
D5 Advanced	0.3
D4 Biodiesel	0.2
Total	~2.5

Source: EPA, Citi Research

Skyrocketing Renewable Identification Number (RIN) prices and the E10 gasoline 'blend wall' are once again making waves for policymakers, US refiners and domestic producers/users of corn and soy. The US Environmental Protection Agency (EPA) has major decisions to consider regarding future Renewable Fuel Standards (RFS2) rule proposals and the extent it wishes to provide policy relief for a program that we argue would become too binding and unsustainable by the end of 2014. US Congress could act first on the back of hearings held on the subject in July. But the politics behind such a move remain divisive. And unless high RIN prices lead directly to a sustained increase in retail gasoline prices—something markets probably will not observe until 2014—legislative action might not be imminent. But the EPA as administrator of the law can act on its own without political cover and this seems a plausible course for 2014.

Figure 4. Conventional and Advanced RIN prices have surged and converged this year...



Source: Starfuels Inc., Citi Research

¹ Previously published RINS research for further background by Aakash Doshi and Eric G Lee →
March 2013: [ABCs of RINS](#) and [RIN Mechanics](#) | July 2013: [Lord of the RINS Flash Comment](#)

The RIN Backdrop

For the first time since the passage of the 2007 EISA legislation—obligated parties (US refiners and gasoline importers) are faced with a true market dislocation—fast approaching a physical ‘blend wall’ whereby volumetric blending mandates dictated by RFS2 cannot be physically achieved in 2013 without the drawing down of carryover RIN credits...

The clash between aggressive volumetric quotas to blend renewable fuels into the final US gasoline (and diesel) supply (Figure 2) established via the 2007 EISA law and enforced by the EPA is rippling through the US refining system amid a structural decline in domestic gasoline consumption. For the first time since the passage of the legislation, this year obligated parties (US refiners and importers) are faced with a physical conundrum. **2013 statutory rules require blending 13.8-bn gal of conventional renewable fuel to comply with 134-bn gal of domestic gasoline consumption (Figure 5); forcing an unprecedented drawdown of RIN credits.** Obligated parties (OP) are thus approaching a physical wall since blends above E10 are limited in size by exceptional waivers (E15) or lack of demand (E85).

Figure 5. Volumes Used to Determine the Proposed 2013 Percentage Standards*

bn-gal	Total domestic use	Renewable Volume portion	Net non-renewable volumes	%age standard	Renewable Fuel Type (bn gal unless noted)
Gasoline	133.7	12.85	120.85	0.008%	Cellulosic biofuel (14-mn gal)
Diesel	52.26	1.23	51.03	1.12%	Biomass-based diesel (1.92)
Total	185.96		171.88	1.60%	Advanced biofuel (2.75)
				9.63%	Renewable Total (16.55)

Source: EIA, EPA, Citi Research, *renewable fuel volumes subtracted from total gasoline and diesel use; biodiesel is part of the advanced carve-out and the 1.92-bn gal is in ethanol equivalent (EE) terms; physical ethanol need is near the blend wall point (E10)—a market poised near saturation amid a drawdown of pricy RIN credits.

...Sufficient quantities of banked ‘paper’ RIN credits do exist in order to ensure compliance this year. But as RFS2 becomes even more binding in 2014/2015 the policy would become unsustainable absent ongoing annual EPA waivers or a permanent legislative fix...


Carryover banked RIN credits of ~2.5-bn gal (Figure 3) ensure that compliance can be achieved in 2013. Looking forward the task becomes extremely onerous in 2014 and unsustainable by 2015 without policy easing or a push out of the E10 blend wall since OPs must continue to source a scarcity of RINs. Markets have taken notice of the policy challenges the EPA faces in maintaining current RFS2 targets. The price of conventional (D6) RINs are averaging ~\$1.15/gal this quarter—a nine-fold jump from levels in January and a measurable 15% rise from their prior peak in March to just north of \$1 (Figure 4). The convergence of D6 and advanced RIN prices this year also implies the market already is or will be short credits (or at minimum, specs are willing to go long RINs) absent policy adjustment, though the recent price drop from \$1.40/gal to the \$0.9-\$1.10 range is likely due to market optimism of some sort of rules change. To be sure, the acceleration of RFS2 mandates in 2014 to 3.75-bn gal advanced biofuels out of 18.15-bn gal in aggregate renewables suggests required ethanol blending volumes near 16-bn gal (14.4-bn gal conventional, ~1.6-bn gal or more towards the advanced carve-out), exceeding domestic nameplate production capacity of ~14-bn gal/annum for the first time in history (Figures 6, 7).

Figure 6. US Nameplate Fuel Ethanol Plan Production Capacity*

PADD	Number of Plants	2013	
		Nameplate Capacity	
		(bn gal/year)	(k b/d)
PADD 1	4	360	23
PADD 2	172	12,598	822
PADD 3	5	419	27
PADD 4	5	190	12
PADD 5	7	285	19
U.S. Total	193	13,852	903


Source: DOE, Citi Research, *as of January 2013

Figure 7. US Ethanol Production and Blending Levels (2009 – Present)




Source: EIA, Citi Research

Figure 8. Simple Dry Mill Ethanol Plant Margins



Source: Citi Research

Figure 9. US Ending Stocks of Fuel Ethanol



Source: EIA, Citi Research

Figure 10. US Corn Balances*

Millions of Acres Millions of Bushels				USDA Estimates		Citi Estimates	
	09/10	10/11	11/12	12/13	13/14	12/13	13/14
Area Planted	86.5	88.2	91.9	97.2	97.4	97.2	96.5
Area Harvested	79.6	81.4	84.0	87.4	89.1	87.4	88.2
Percent Harvested	92%	92%	91%	90%	92%	90%	91%
Yield per Harvested Acre	164.9	152.8	147.2	123.5	156.5	123.4	158.0
Beginning Stocks	1,673	1,707	1,127	988	729	989	769
Production	13,131	12,447	12,360	10,780	13,950	10,780	13,936
Imports	10	28	29	160	30	120	10
Total Supply	14,814	14,182	13,516	11,929	14,709	11,889	14,715
Feed and Residual	5,550	4,795	4,545	4,450	5,150	4,350	5,225
Ethanol Usage	4,591	5,019	5,011	4,650	4,900	4,660	4,875
Food, Seed and Industrial	5,565	6,426	6,439	6,050	6,350	6,030	6,325
Total Domestic Usage	11,115	11,220	10,985	10,500	11,500	10,380	11,550
Exports	1,900	1,834	1,542	700	1,250	740	1,350
Total Demand	13,015	13,054	12,527	11,200	12,750	11,120	12,900
Ending Stocks	1,799	1,128	989	729	1,959	769	1,815
Stocks to Usage	13.8%	8.6%	7.9%	6.5%	15.4%	6.9%	14.1%

Source: USDA, Citi Research, *subject to revision; published on 15 July 2013

Muddling through 2013...

Lower grain prices are forecast for the next several quarters pointing to a y/y increase in corn use for ethanol but the E10 blend wall still remains an impasse...

During most of 2012 and 1H'13, record high cash corn prices severely compressed ethanol production margins, even to negative levels, before the recent rebound. The expiration of both a blender tax credit and import tariff in 2012 further impacted unfavorable output economics buttressing a sharp and steady draw on US ethanol inventories during 1H'13—of about 30% to ~16-mn bbls—after holding more ample levels in 2012 (Figures 8, 9) amid ~100-k b/d y/y decline in output. Coarse grain prices falling to three-year lows in recent weeks (Figure 1), pursuant Citi forecasts which project [~\\$4.50-\\$5.25/bu CBOT corn prices](#) to persist through cal'14 should help keep ethanol production margins strong and positive. Elevated RIN prices and the perceived lack of RIN credits also encourages maximum physical blending into the E10 pool and the y/y increase in US corn use for ethanol is estimated to rise by over 200-mn bushels for the new-crop marketing year to ~4.88-bn bushels (Figure 10). In the short-term we expect production to remain around 850-870-k b/d this year and unlikely to push much harder than 900-k b/d in 2014 given physical capacity constraints and strained utilization rates.

While higher levels of ethanol output were seen in 2011-12, the corn price spike during the 3Q'12 drought forced some plant closures, keeping capacity lower. With improving margins there is the return of economic incentives for ethanol plants to produce again, but given the blend wall, incremental output might target the export market amid signals that policymakers might look to ease standards.

Figure 11. Potential path to 2013 RFS2 compliance for 16.55-bn gal of renewable fuel blending

	Conventional Renewable Fuels	Biomass Diesel, Other Biofuels	Cellulosic Biofuels
<i>Requirement</i>	13.8-bn gal	2.736-bn gal	0.014-bn gal
<i>Potential Fuel and Credit Mix</i>	12.6-bn gal corn ethanol, 1.2-bn gal paper RINs	~0.6 to 0.8-bn gal Brazilian sugar ethanol with balance met with domestic output, paper RINs, plus 1.92-bn gal biodiesel	0.014-bn gal
<i>Comment</i>	~830-k to 840-k b/d domestic ethanol output and drawdown of more than half of the banked D6 RINs	the arb window to Brazil is open and encourages maximum use of 'advanced' sugar ethanol up to blend wall; 1.28-bn gal biomass diesel volume is a statutory requirement equaling 1.92-bn gal towards the total RFS2 amount	capacity should allow for this portion to be met with physical product

Source: EPA, Citi Research

RFS2 and other policies have succeeded in building out once nascent US ethanol infrastructure since 2005 despite the off/on idling of capacity. Ethanol use as a low cost octane in the domestic gasoline supply is now embedded in the US energy complex with or without the RFS2. **E5 to E10 blending levels and ethanol replacing MBTE as oxygenate for clean gasoline is not a problem for refiners in percentage terms. Rather, the growing volumetric blending requirement is the main issue** (especially considering that 134-bn gal of estimated final gasoline supply for 2013 is a ~5% decline from the late 2000s with EIA projections pointing to even lower 2014 levels at 132-bn gal).

...Additional volumes of ethanol must therefore be consumed as higher blend levels such as E15 or E85...

As the *EPA itself acknowledges*, as the volume requirements of the RFS program rise, it is increasingly necessary that the amount of ethanol that must be blended to meet those requirements exceeds the amount that can be consumed as E10. Additional volumes of ethanol must then be consumed as higher blend levels such as E15 or E85. While higher-nested biofuels can also be used to meet the RFS2 conventional carve-out, traditional ethanol will continue to dominate the overall mix (more than 85% of total renewable fuel product). And with the E10 market saturating and RINs becoming more difficult (costly) to source, there is no release valve other than E15 and E85 which have idiosyncratic obstacles and their own shortcomings. Thus, many OPs are already constrained by an RVO (renewable volume obligation) of ethanol blending that cannot be legally or practically consumed for 2013.

...which are needed in 2014 to provide an outlet for a market that is short RINs.


Perhaps to the chagrin of the refining sector—the EPA seems keenly aware of this contradiction. To be sure, the *agency has also suggested* it is comfortable with high RIN prices persisting. In theory, this should encourage higher level blends; an open policy objective. Given sufficient RIN carryover (the full 2.5-bn gal which fell below the 2012 rollover cap) the EPA appears comfortable even if “all [carryover RINs are] used for compliance purposes in 2013” thereby allowing physical blending to occur below the E10 wall. But although E15 or E85 are not needed in significant volumes for 2013, higher blends are sine qua non in providing outlets for 2014 compliance. **This is why the EPA is likely to weigh the growing RIN deficit and to open up a longer comment period to provide early guidance for stakeholders for 2014 proposals with a final 2013 decision perhaps arriving later this month.**

EPA waivers do require observance of “severe economic harm”—a somewhat obfuscated consideration—but given the physical program constraints fast approaching and the fact that gasoline prices could spike (see below) at a measurable cost to consumers, the agency could be more flexible on the program than it was during the 2012 drought when officials denied temporary waivers.

In this context, for 2013 compliance we estimate a significant reduction in carryover RINs available for 2014 (Figure 11) to a best-case scenario between 0.5-bn gal to 1-bn gal; with about 1.2-bn gal drawn down for the conventional carve-out and the probable exhaustion of nearly all advanced RINs. Obligated parties near the blend wall in 2013 would almost certainly crash through it in 2014 unless they significantly reduce RVOs by cutting throughput or increasing exports (since mandates are limited to final *domestic* supply only); likely resulting in higher compliance costs, higher US gasoline prices and a still unsustainable mandate.


Looking to 2014 and beyond...

Figure 12. D4 RIN Prices Closely Track Biodiesel Blending Margins...



Source: Bloomberg, Starfuels Inc., Citi Research

Figure 13. Estimated D6 RIN Carryover During the RFS2 era




Source: Citi Research estimates

Figure 14. US Soybean Oil Balances

(Mn lbs)	09/10	10/11	11/12	12/13	13/14
Carryin (Oct. 1)	2,861	3,406	2,378	2,540	1,745
Production	19,615	18,873	19,620	19,605	19,495
Imports	103	159	149	350	250
Total Supply	22,579	22,438	22,147	22,495	21,490
Domestic Use	15,814	16,827	18,193	18,550	18,500
Biodiesel	1,622	2,737	4,870	4,800	5,500
Non-Biodiesel	14,192	14,090	1,323	13,750	13,050
Exports	3,359	3,233	1,464	2,200	1,300
Total Use	19,173	20,060	19,657	20,750	19,800
Carryout (Sep. 30)	3,406	2,378	2,490	1,745	1,690

Source: USDA, Citi Research


Figure 15. US Biodiesel Production (2011 – May 2013)



Source: EIA, Citi Research

RFS2 is driving the wedge of RINs this year for which sufficient availabilities may disappear by end of 2014 (Figures 13, 16) and even when considering the US government's own projections. US Department of Energy figures suggest a dislocated RFS2 policy without EPA issuance of credits and ongoing annual waivers. The pace of biofuels capacity additions and structural easing of US transportation fuel supply are simply too far off the stated policy targets. And if no relief is provided in 2014, we would argue the RFS2 mandate could fall apart a year from now as the market would run out of sufficient RINs or RIN generation capacity to meet the volumetric blending requirements.

Figure 16. Shortfall in credits from RFS2*



Source: EIA, *bn credits

If not waivers or curtailed requirements the other side of the coin is pushing up the physical blend wall...although this faces its own difficult hurdles.

Obligated parties potentially self-medicating via reduced refinery runs, allocating throughput to non-RFS2 regulated products (i.e. HO, jet fuel) and curtailing imports/increasing gasoline exports could also be a meaningful development; eventually leading to reduced domestic gasoline/diesel supply and thereby making the domestic transportation fuel market more volatile and less secure.

As such, potential fixes (some temporary) previously proposed by Citi and other market participants include:

■ **Partial EPA waiver/2013 flat:** the EPA has flexibility with the advanced carve-out and has utilized this for several years now; the cellulosic requirement was reduced 99.9% to 14-mn gal (EE terms) from 1-bn gal in 2013 (lack of production capacity). The waiver of cellulosic biofuels under any scenario is almost guaranteed for 2014 as well. But while acceding to this change, the total advanced biofuels amount has remained the same (i.e. 2.75-bn gal in 2013) meaning the EPA expected the gap to be filled from sugar-based ethanol from Brazil, biodiesel and carryover RINs. Hence a proposal is to not only waive the cellulosic constituent (i.e. what would be 1.75-bn gal EE in 2014) but actually cut the entire advanced biofuels amount to ~2-bn gal. This would reduce the 2014 total mandate to 16.45-bn gal—slightly below 2013's 16.55-bn gal, allowing a modest 'kick-the-can' fix until Congress might act post-2014 elections (for the 2015 rule).

■ **E15 / E85:** the other side of the coin is raising the physical blend wall. Certainly if US gasoline and diesel final supply were to increase it would allow current blending rates to hold or perhaps even rise without saturating E10. But given the structural decline in demand and fleet efficiency, the other option is pushing higher level ethanol blends. But this also faces infrastructure and consumer constraints as well as price distortions.

- **Infrastructure:** less than 1% of the US vehicle fleet are flex fuel vehicles capable of using an E85 blend which is only available at 2% of nationwide retail stations largely concentrated in a few states such as Minnesota, Iowa and California. E15 faces similar lack of distribution capacity and labeling issues even though it has a much larger potential consumer base.
- **Consumer preference:** although the EPA has issued E15 waivers for autos after MY2001—industry players, auto manufacturers and several consumer groups have all avoided broad adoption. Some argue blends above E10 distribute too much heat, impacting parts and leading to engine failure. The mix of water and alcohol in greater concentrations could also cause an undue attraction and warping of parts. Additionally this waiver does not include motorbikes or light-duty trucks and some manufacturers might void warranties. Many retailers also do not want to add E85 pumps with the liabilities associated with them and the added costs to their filling stations. Thus, an immediate push to E15 / E85 adoption seems less feasible.
- **Cost:** while ethanol trades at a discount to clear gasoline on \$/gal terms, it often trades at parity or premium in energy equivalent terms. For 2013 this is not an issue—since the market is still only near the blend wall and the octane value of ethanol is still a positive benefit for consumers. Its normal E10 use also lowers the consumption of more expensive neat gasoline which typically trades at a premium. Market dynamics could change when crossing the blend wall in 2014. Higher RIN prices given an RFS2 potential shortfall of ~2-bn gal+ could distort physical ethanol pricing versus RBOB, prompting ethanol relative

Figure 17. Renewable Fuel Equivalence Value

Product	Ethanol Equivalence Value
Conventional Ethanol	1x
Cellulosic biomass ethanol	2.5x
Biodiesel	1.5x
Butanol	1.3x
Non-ester renewable diesel	1.7x
Other renewables (crude linked)	1x

Source: EPA, Citi Research

■ **Biodiesel/D4/ethanol equivalence value adjustment:** solutions could also link to the US biodiesel market which Citi discussed in July. Within the advanced carve-out, biodiesel mandates enjoy flexibility, as they are issued new each year (i.e. 1.28-bn gal for 2013 in volume terms, 1.92-bn gal in EE terms). It can be assumed that the standard on volume terms will at least remain the same for 2014. However, adjusting the biodiesel (D4) RIN market in ethanol equivalent terms from 1.5x (Figure 17) to 2x or even 3x or 4x is an accounting metric that could meaningfully reduce RIN generation costs (which ultimately underpins the dilemma with RFS2 for future years which is the lack of low-cost RIN generation capacity given the blend wall). This also solves the issue in that advanced/biodiesel RINs are facing an even larger potential shortfall than the D6 market given lower blending rates (~3%) vis-à-vis the E10 gasoline pool. For example a volumetric spike in 2014 of 0.5-bn gal to 1.78-bn gal biodiesel valued at 3x-ethanol equivalent terms could generate 5.3-bn RINs—more than adequate to cover the potential 2-bn gal+ shortfall for 2014. Of course this ‘paper’ solution might not meet the spirit of RFS2, but even a more modest jump to 2-2.5x could provide a potential relief valve for 2014 at perhaps the least harm solution, especially given D4 RINs are quickly exhausting but could be used to fulfill the lower nested conventional carve-out with the eventual depletion of D6 inventory.

Operable domestic production capacity for biodiesel is over 2-bn gal per annum with about 2/3 of this available within PADD II. USDA estimates point to a 15% increase in soybean oil production (a biodiesel feedstock) in the coming harvest year on the back of what Citi estimates will be a 10% jump in the US soybean crop size to over 3.3-bn bushels for 2013/14 with bean prices forecast to plunge y/y ~15%. Domestic biodiesel output has already surged in 1H’13 (Figure 15) along with D4 RIN prices which are closely tracking blending margins (Figure 12). But sales of B100 in biodiesel blends remain unimpressive y/y and the differential between biodiesel prices and ultra low sulphur diesel have blown out this year; suggesting that a paper solution might also be needed to provide the physical market some support.

This is also linked to how high can D6 RIN prices might go this year. The theoretical max cost (breakeven) RIN price should be the penalty for non-compliance. Realistically, conventional RIN prices can converge to biodiesel RIN prices. Current margins (ULSD – Biodiesel spot + blending credit) appear to be the main component for D4 prices. Assuming a market without D6 RIN stocks, compliance could be met with these higher category biofuels. The problem is that 2013 targets are already becoming so binding, the diesel market itself faces major RIN shortfalls and the entire RFS2 market outlook is one that is short credits; so RIN price convergence and elevation would persist without policy adjustment and D4 provides a ‘multiplier’ effect that would allow for quicker generation of new RINs.

Figure 18. US Ethanol Output Capacity by Market Share

	2012 Production Capacity (bn gallons per annum)	Share of Total Output Capacity
Archer-Daniels Midland	1,720	11.6%
POET LLC	1,629	11.0%
Valero Energy Corp.	1,130	7.6%
Green Plains Renewable	730	4.9%
Aventine Renewable Energy Holdings Inc.	460	3.1%
Koch Industries	440	3.0%
Abengoa SA	378	2.5%
Big River Resources LLC	350	2.4%
The Andersons Inc.	330	2.2%
White Energy Holding Co. LLC	258	1.7%

Source: BI, Citi Research

At some level of RINs prices, there arises the incentive to generate RINs, with the high price of RINs allowing final E15 / E85 to be heavily discounted. OPs or other entities could produce higher level blends and dump them on the market and generate RINs, as long as RIN prices were greater than the cost of producing, storing, discounting to sell higher percentage blends. Recently, there have been reports of ethanol producers (non-OPs) selling E85 directly to retailers, banking a high-price RIN that could be sold to an obligated party that was short RINs. Absolute Energy in Iowa was offering E85 at \$1.93/gal, versus average Iowa E85 prices of \$2.77, subsidized by RIN credits; RIN prices were over \$1 at that point. There could be the incentive for refiners/blenders to do similarly. Nevertheless, the cost to comply still accrues to OPs, whether they can or cannot use this means to generate RINs for their own needs, or to sell them onwards.

In short, while this market arbitrage aids RFS2 compliance, it represents a direct cost to obligated parties. Furthermore there appears to be a growing dislocation between obligated parties and ethanol producers. Looking at the large US refiners—Valero, ExxonMobil, Marathon or Phillips66—only Valero has any sizable ethanol production capability (Figure 18). Given that RIN generation was largely a non-issue in 2012 (despite the Midwestern drought) on volumetric terms—statements from various market participants lead us to believe the majority of carryover RINs were held by OPs coming into 2013. But this figure is poised to fall in 2014 both on a total carryover basis and the portion held by obligated parties.

Not all market participants are hit equally by RFS2 mandates...

But all market players are not being hit equally since RFS2 outcomes clearly favor certain portions of the supply chain. Retailers (Susser, Murphy, Pantry) seem to be benefiting from RIN prices. Firms like Western have pointed to it meeting 85% of its RINs obligation and its retail business is helping it find an outlet. OPs in the midstream space that supply small amounts of gasoline through blending are also largely unaffected given small RVOs. Most of the majors can also muddle through compliance (at least in 2013) with CVX, Shell and BP all reportedly net long RINs. Exxon may be slightly short and brokers markets suggest a net seller of RINs back during 1Q'13, but the largest US major now states it is a net buyer of RIN credits with the recent surge in prices having only a small impact on its profit.

...independent refiners (all of whom are obligated parties) are the loudest voice in opposition to the current policy trajectory.

This ultimately leads to the constituency that is most adversely impacted by RFS2; independent refiners that are mostly short RINs. CVR has pointed to the RFS2 system as being broken and claims 'severe hardship' expecting to spend \$200-\$240mn on compliance in 2013. Larger independents such as Valero claim much higher RFS2 costs of nearly \$800mn. Others such as MPC, PSX and PBF are also estimated to be net short from \$200-\$500mn each with PBF expecting some policy announcement from the EPA or Congress in the next few months. Independents are pointing out that 20-60% of the costs are being passed through but it impacts their margins since blended barrels are being sold at a discount to spot in account of the RIN value. Independent refiners represent the loudest voice of all obligated parties that is calling for significant RFS2 policy relief.

- **Congressional amendment wild card:** evaluating the broader political dynamics at play offers insight into the two major political wildcards – policy intervention by either Congress or the EPA.
 - In the House, the Energy and Commerce Committee has been holding hearings on RFS with dozens of stakeholders participating. **Outright repeal of RFS2 is unlikely and any deals struck are likely to target reforms.** But with major constituencies including the oil and biofuels lobby at odds, the livestock/grocer and corn farmer lobby at odds, the environmental community


Given the EPA's broad policy agenda, RFS2 / RINs look like a place the agency might compromise rather than fight a protracted battle; providing Congress some breathing room beyond the mid-term elections...

split and persistent Congressional gridlock, a comprehensive legislative fix may be slow to materialize absent ratcheting public pressure as a result of potentially higher gasoline prices next year.

- EPA intervention in 2013/2014 to provide a short-term fix therefore looks like a more likely probability. Our view is that given the EPA's larger agenda and relationship with the House, RINs look like a place to compromise rather than stand and fight a protracted battle, for several reasons. First, legislative efforts are underway in the House to significantly de-fund the EPA and the agency is already fighting to stave off large cuts. Second, Obama has made climate change a priority in his second term and the EPA is the chief architect of his core policies in the power sector (see: "[Much Ado About Climate Change](#)" Citigroup: 25 June 2013). The House Republicans are already challenging the EPA's ability to regulate power plant emissions, and we think this battle is more central to the President's environmental agenda than the RFS. Finally, the administration will be highly sensitive to potential spikes in gasoline prices going into the 2014 elections, especially if opponents charge they are caused by the EPA. In short, the EPA probably will not "win the battle to lose the war". Ultimately, a legislative amendment looks needed for a real fix (i.e. move to a percentage rather than volumetric standard) since EPA waiver authority requires annual action. But the EPA can provide a buffer for this process.

Gasoline prices today not measurably impacted...but this could change in the near future...

Figure 19. Gasoline Crack Spreads for US East Coast, US Gulf Coast




Source: Bloomberg, OPIS, Citi Research

Gasoline cracks have not yet been significantly impacted by RIN prices but could play a larger factor in 2014...

Spot gasoline cracks have not yet been significantly impacted by RIN prices.

The sharp summer surges have been partially seasonal due to the uptick of driving season and summer spec gasoline. But in 2012, this was exacerbated by refinery closures in Europe and on the US East Coast, which created tightness in particular among gasoline blending components. This was compounded by refinery outages as Hurricane Sandy swept through the East Coast, leaving gasoline inventories low. The broken Venezuelan refinery system meant greater pull on products from Latin America. In 2013, spots of strong gasoline demand in Africa and the Middle East was joined by further refinery issues and the need to build-up gasoline stocks post-

Figure 20. Brent – RBOB Crack (Seasonal)



Source: Bloomberg, Citi Research

The potential for policy easing in 2014 appears more likely than not and greater than 50% towards an 'easier' mandate...likely via the EPA as a temporary fix until legislative measures can be passed by Congress. Any RFS2 relaxation would be bearish RIN prices; absent which RIN levels should continue to rise in 2014 in a severely more binding environment.

Sandy. But this summer, the long awaited start-up of the Motiva Port Arthur refinery and better connectivity between the Gulf Coast and the East Coast via an expanded Colonial pipeline has meant a better supplied East Coast and adequate inventory levels. Against this backdrop, RINs prices have not been the major factor, although traders do report that RIN prices have been modestly driving some gasoline crack moves. But only when these spreads surge significantly would they hit US gasoline prices - particularly at the pump - as obligated parties potentially avoid supplying the domestic market so as not to incur the cost of the RIN.

While prompt RBOB cracks have so far shown little impact from RINS, looking down the curve at winter cracks (versus Brent) it does look as if the possibility of a run up in RINS into expiry is a concern for the market (Citi has recommended shorting this crack for fundamental reasons in its [3Q'13 Commodities Market Update: Curb Your Enthusiasm](#)). December 2013 RBOB-Brent cracks are currently trading near \$10/bbl; after Hurricane Sandy in 2012 (a perfect storm for the East Coast refining complex) the RBOB-Brent crack averaged \$3.3/bbl in December 2012, while fundamentals for gasoline are significantly weaker this year given 7.5% rise in inventories y/y nationwide and 14.2% on the East Coast. RFS2 policy easing is clearly bearish RIN prices but it could also be bearish cracks.

Will there be an end to RINsanity?

Ultimately a legislative amendment would be needed by 2015 (if not sooner) to permanently resolve RFS2. While full repeal is unlikely, even a dramatic move to a pure 'percentage-based' measure (driven by legislative action) is not out of the picture and has been mentioned by obligated parties and suggested by some members of Congress. However, with the debt ceiling debate and mid-term season fast approaching, legal amendments might not be imminent; the EPA may need to issue waivers without legislative cover. To be sure, any sizable policy easing in the interim—even if it were to be implemented or adjusted as far out as 2015—would be bearish RIN prices; improving the prospects for both RIN carryout y/y and stock levels (at the 20% cap) as well as new RIN creation, in a less binding environment. We reiterate our view published in 1Q'13 that suggested the EPA will probably make no changes for 2013, a greater than 50% probability for some policy easing in 2014 and a 100% chance (need) for 2015 given the current RFS2 trajectory.

Traded RIN levels are likely to stay elevated, various categories near parity amongst each other given a systemic shortfall and prices are poised to rise further in 2014 absent policy change (the recent pullback might be indicative of market expectations for some easing although prices seem sticky at ~\$1). Biodiesel margins likely remain a source of current price discovery but going forward everything could lift. If there were no change in policy, RIN prices need to move higher, to incentivize different types of adjustments. A theoretical maximum cost should be the penalty for non-compliance. This stands at \$32,500 per day per instance of non-compliance, as stipulated in the Clean Air Act. This might be manageable for obligated parties that were only modestly short RINs and only on a temporary basis. But this does not seem to be the case since annual compliance cost estimates are in the \$100s of millions for many independent refiners.

This essentially means a different level of tolerance for different OPs, depending on their net short RIN position. At some level below this, RIN obligations may become too onerous, in which case, OPs would opt to avoid supplying the domestic market, discouraged by high RIN prices. At some level, OPs and non-OPs may look to earn RIN credits by blending more than the ethanol needed for RVOs, through higher blends like E15 or E85; this would require RIN prices high enough to encourage this, where the cost of ethanol and gasoline are more than offset. Given current

levels of ~\$2.30 for ethanol and ~\$3 for gasoline, RINs may need to reach over \$3 to incentivize this on a wider basis; and this would still not solve the current impasse. Severely limited E85 fueling infrastructure and final demand means that this would be far from sufficient to plug the RIN shortfall in 2014.

With the prospect of a RIN driven price spike in transport fuel markets in 2014, it might then prompt Congressional action which lacks a clear mandate or much prospects of a tangible deal in the short-term; the House energy committees finally taking some notice of the policy contradiction in the past few months holding hearings with dozens of stakeholders. While pro-RFS2 constituents might keep pressing for a broader adoption of midlevel blends, this is also not a near term solution for obligated parties that are likely to face a severe compliance shortfall as soon as this year let alone for 2014 (despite, interestingly enough, that as discussed E15 / E85 provides one of the few modest outlets for RIN generation in 2014). As such, the EPA could act sooner rather than later to provide a market relief valve before the risk of stalled and volatile US gasoline and diesel system forces its hand. The final 2013 decision which was expected in July could arrive this month or later this quarter. The 2013 rule is likely to remain intact, however, with EPA and White House support appearing to favor policy relaxation beginning with the 2014 rule.

Appendix A-1

Analyst Certification

The research analyst(s) primarily responsible for the preparation and content of this research report are named in bold text in the author block at the front of the product except for those sections where an analyst's name appears in bold alongside content which is attributable to that analyst. Each of these analyst(s) certify, with respect to the section(s) of the report for which they are responsible, that the views expressed therein accurately reflect their personal views about each issuer and security referenced and were prepared in an independent manner, including with respect to Citigroup Global Markets Inc and its affiliates. No part of the research analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) expressed by that research analyst in this report.

IMPORTANT DISCLOSURES

Analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates ("the Firm"). Like all Firm employees, analysts receive compensation that is impacted by overall firm profitability which includes investment banking revenues.

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citi Research product ("the Product"), please contact Citi Research, 388 Greenwich Street, 28th Floor, New York, NY, 10013, Attention: Legal/Compliance [E6WYB6412478]. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm's disclosure website at https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures. Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Historical disclosures (for up to the past three years) will be provided upon request.

NON-US RESEARCH ANALYST DISCLOSURES

Non-US research analysts who have prepared this report (i.e., all research analysts listed below other than those identified as employed by Citigroup Global Markets Inc.) are not registered/qualified as research analysts with FINRA. Such research analysts may not be associated persons of the member organization and therefore may not be subject to the NYSE Rule 472 and NASD Rule 2711 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account. The legal entities employing the authors of this report are listed below:

Citigroup Global Markets Inc

Aakash Doshi; Eric G Lee; Edward L Morse; Anthony Yuen; Xing Xing

Citigroup Global Markets Ltd

Seth M Kleinman; Christopher J Main

OTHER DISCLOSURES

For securities recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in the issuers' financial instruments and may act as principal in connection with such transactions. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the Product. The Firm regularly trades in the securities of the issuer(s) discussed in the Product. The Firm may engage in securities transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal basis.

Securities recommended, offered, or sold by the Firm: (i) are not insured by the Federal Deposit Insurance Corporation; (ii) are not deposits or other obligations of any insured depository institution (including Citibank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures section of the Product. The Firm's research department has received assistance from the subject company(ies) referred to in this Product including, but not limited to, discussions with management of the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of the Product. Although Citi Research does not set a predetermined frequency for publication, if the Product is a fundamental research report, it is the intention of Citi Research to provide research coverage of the/those issuer(s) mentioned therein, including in response to news affecting this issuer, subject to applicable quiet periods and capacity constraints. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in the Product must take into account existing public information on such security or any registered prospectus.

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by. The Product is made available in Australia through Citi Global Markets Australia Pty Ltd. (ABN 64 003 114 832 and AFSL No. 240992), participant of

the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in Australia to Private Banking wholesale clients through Citigroup Pty Limited (ABN 88 004 325 080 and AFSL 238098). Citigroup Pty Limited provides all financial product advice to Australian Private Banking wholesale clients through bankers and relationship managers. If there is any doubt about the suitability of investments held in Citigroup Private Bank accounts, investors should contact the Citigroup Private Bank in Australia. Citigroup companies may compensate affiliates and their representatives for providing products and services to clients. The Product is made available in **Brazil** by Citigroup Global Markets Brasil - CCTVM SA, which is regulated by CVM - Comissão de Valores Mobiliários, BACEN - Brazilian Central Bank, APIMEC - Associação dos Analistas e Profissionais de Investimento do Mercado de Capitais and ANBID - Associação Nacional dos Bancos de Investimento. Av. Paulista, 1111 - 11º andar - CEP. 01311920 - São Paulo - SP. If the Product is being made available in certain provinces of **Canada** by Citigroup Global Markets (Canada) Inc. ("CGM Canada"), CGM Canada has approved the Product. Citigroup Place, 123 Front Street West, Suite 1100, Toronto, Ontario M5J 2M3. This product is available in **Chile** through Banchile Corredores de Bolsa S.A., an indirect subsidiary of Citigroup Inc., which is regulated by the Superintendencia de Valores y Seguros. Agustinas 975, piso 2, Santiago, Chile. The Product is made available in **France** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. 1-5 Rue Paul Cézanne, 8ème, Paris, France. The Product is distributed in **Germany** by Citigroup Global Markets Deutschland AG ("CGMD"), which is regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). CGMD, Reuterweg 16, 60323 Frankfurt am Main. Research which relates to "securities" (as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong)) is issued in **Hong Kong** by, or on behalf of, Citigroup Global Markets Asia Limited which takes full responsibility for its content. Citigroup Global Markets Asia Ltd. is regulated by Hong Kong Securities and Futures Commission. If the Research is made available through Citibank, N.A., Hong Kong Branch, for its clients in Citi Private Bank, it is made available by Citibank N.A., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. Citibank N.A. is regulated by the Hong Kong Monetary Authority. Please contact your Private Banker in Citibank N.A., Hong Kong, Branch if you have any queries on or any matters arising from or in connection with this document. The Product is made available in **India** by Citigroup Global Markets India Private Limited, which is regulated by Securities and Exchange Board of India. Bakhtawar, Nariman Point, Mumbai 400-021. The Product is made available in **Indonesia** through PT Citigroup Securities Indonesia. 5/F, Citibank Tower, Bapindo Plaza, Jl. Jend. Sudirman Kav. 54-55, Jakarta 12190. Neither this Product nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens wherever they are domiciled or to Indonesian residents except in compliance with applicable capital market laws and regulations. This Product is not an offer of securities in Indonesia. The securities referred to in this Product have not been registered with the Capital Market and Financial Institutions Supervisory Agency (BAPEPAM-LK) pursuant to relevant capital market laws and regulations, and may not be offered or sold within the territory of the Republic of Indonesia or to Indonesian citizens through a public offering or in circumstances which constitute an offer within the meaning of the Indonesian capital market laws and regulations. The Product is made available in **Israel** through Citibank NA, regulated by the Bank of Israel and the Israeli Securities Authority. Citibank, N.A., Platinum Building, 21 Ha'arba'ah St, Tel Aviv, Israel. The Product is made available in **Italy** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. Via dei Mercanti, 12, Milan, 20121, Italy. The Product is made available in **Japan** by Citigroup Global Markets Japan Inc. ("CGMJ"), which is regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka Securities Exchange. Shin-Marunouchi Building, 1-5-1 Marunouchi, Chiyoda-ku, Tokyo 100-6520 Japan. If the Product was distributed by SMBC Nikko Securities Inc. it is being so distributed under license. In the event that an error is found in an CGMJ research report, a revised version will be posted on the Firm's Citi Velocity website. If you have questions regarding Citi Velocity, please call (81 3) 6270-3019 for help. The Product is made available in **Korea** by Citigroup Global Markets Korea Securities Ltd., which is regulated by the Financial Services Commission, the Financial Supervisory Service and the Korea Financial Investment Association (KOFIA). Citibank Building, 39 Da-dong, Jung-gu, Seoul 100-180, Korea. KOFIA makes available registration information of research analysts on its website. Please visit the following website if you wish to find KOFIA registration information on research analysts of Citigroup Global Markets Korea Securities Ltd. <http://dis.kofia.or.kr/fs/dis2/fundMgr/DISFundMgrAnalystPop.jsp?companyCd2=A03030&pageDiv=02>. The Product is made available in Korea by Citibank Korea Inc., which is regulated by the Financial Services Commission and the Financial Supervisory Service. Address is Citibank Building, 39 Da-dong, Jung-gu, Seoul 100-180, Korea. The Product is made available in **Malaysia** by Citigroup Global Markets Malaysia Sdn Bhd (Company No. 460819-D) ("CGMM") to its clients and CGMM takes responsibility for its contents. CGMM is regulated by the Securities Commission of Malaysia. Please contact CGMM at Level 43 Menara Citibank, 165 Jalan Ampang, 50450 Kuala Lumpur, Malaysia in respect of any matters arising from, or in connection with, the Product. The Product is made available in **Mexico** by Acciones y Valores Banamex, S.A. De C. V., Casa de Bolsa, Integrante del Grupo Financiero Banamex ("Accival") which is a wholly owned subsidiary of Citigroup Inc. and is regulated by Comision Nacional Bancaria y de Valores. Reforma 398, Col. Juarez, 06600 Mexico, D.F. In **New Zealand** the Product is made available to 'wholesale clients' only as defined by s5C(1) of the Financial Advisers Act 2008 ('FAA') through Citigroup Global Markets Australia Pty Ltd (ABN 64 003 114 832 and AFSL No. 240992), an overseas financial adviser as defined by the FAA, participant of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in **Pakistan** by Citibank N.A. Pakistan branch, which is regulated by the State Bank of Pakistan and Securities Exchange Commission, Pakistan. AWT Plaza, 1.1. Chundrigar Road, P.O. Box 4889, Karachi-74200. The Product is made available in the **Philippines** through Citicorp Financial Services and Insurance Brokerage Philippines, Inc., which is regulated by the Philippines Securities and Exchange Commission. 20th Floor Citibank Square Bldg. The Product is made available in the Philippines through Citibank NA Philippines branch, Citibank Tower, 8741 Paseo De Roxas, Makati City, Manila. Citibank NA Philippines NA is regulated by The Bangko Sentral ng Pilipinas. The Product is made available in **Poland** by Dom Maklerski Banku Handlowego SA an indirect subsidiary of Citigroup Inc., which is regulated by Komisja Nadzoru Finansowego. Dom Maklerski Banku Handlowego S.A. ul.Senatorska 16, 00-923 Warszawa. The Product is made available in the **Russian Federation** through ZAO Citibank, which is licensed to carry out banking activities in the Russian Federation in accordance with the general banking license issued by the Central Bank of the Russian Federation and brokerage activities in accordance with the license issued by the Federal Service for Financial Markets. Neither the Product nor any information contained in the Product shall be considered as advertising the securities mentioned in this report within the territory of the Russian Federation or outside the Russian Federation. The Product does not constitute an appraisal within the meaning of the Federal Law of the Russian Federation of 29 July 1998 No. 135-FZ (as amended) On Appraisal Activities in the Russian Federation. 8-10 Gasheka Street, 125047 Moscow. The Product is made available in **Singapore** through Citigroup Global Markets Singapore Pte. Ltd. ("CGMSPL"), a capital markets services license holder, and regulated by Monetary Authority of Singapore. Please contact CGMSPL at 8 Marina View, 21st Floor Asia Square Tower 1, Singapore 018960, in respect of any matters arising from, or in connection with, the analysis of this document. This report is intended for recipients who are accredited, expert and institutional investors as defined under the Securities and Futures Act (Cap. 289). The Product is made available by The Citigroup Private Bank in Singapore through Citibank, N.A., Singapore Branch, a licensed bank in Singapore that is regulated by Monetary Authority of Singapore. Please contact your Private Banker in Citibank N.A., Singapore Branch if you have any queries on or any matters arising from or in connection with this document. This report is intended for recipients who are

accredited, expert and institutional investors as defined under the Securities and Futures Act (Cap. 289). This report is distributed in Singapore by Citibank Singapore Ltd ("CSL") to selected Citigold/Citigold Private Clients. CSL provides no independent research or analysis of the substance or in preparation of this report. Please contact your Citigold/Citigold Private Client Relationship Manager in CSL if you have any queries on or any matters arising from or in connection with this report. This report is intended for recipients who are accredited investors as defined under the Securities and Futures Act (Cap. 289). Citigroup Global Markets (Pty) Ltd. is incorporated in the **Republic of South Africa** (company registration number 2000/025866/07) and its registered office is at 145 West Street, Sandton, 2196, Saxonwold. Citigroup Global Markets (Pty) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa. The Product is made available in **Spain** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. 29 Jose Ortega Y Gasset, 4th Floor, Madrid, 28006, Spain. The Product is made available in the **Republic of China** through Citigroup Global Markets Taiwan Securities Company Ltd. ("CGMTS"), 14 and 15F, No. 1, Songzhi Road, Taipei 110, Taiwan and/or through Citibank Securities (Taiwan) Company Limited ("CSTL"), 14 and 15F, No. 1, Songzhi Road, Taipei 110, Taiwan, subject to the respective license scope of each entity and the applicable laws and regulations in the Republic of China. CGMTS and CSTL are both regulated by the Securities and Futures Bureau of the Financial Supervisory Commission of Taiwan, the Republic of China. No portion of the Product may be reproduced or quoted in the Republic of China by the press or any third parties [without the written authorization of CGMTS and CSTL]. If the Product covers securities which are not allowed to be offered or traded in the Republic of China, neither the Product nor any information contained in the Product shall be considered as advertising the securities or making recommendation of the securities in the Republic of China. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security or financial products. Any decision to purchase securities or financial products mentioned in the Product must take into account existing public information on such security or the financial products or any registered prospectus. The Product is made available in **Thailand** through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 18/F, 22/F and 29/F, 82 North Sathorn Road, Silom, Bangrak, Bangkok 10500, Thailand. The Product is made available in **Turkey** through Citibank AS which is regulated by Capital Markets Board. Tekfen Tower, Eski Büyükdere Caddesi # 209 Kat 2B, 23294 Levent, Istanbul, Turkey. In the **U.A.E.**, these materials (the "Materials") are communicated by Citigroup Global Markets Limited, DIFC branch ("CGML"), an entity registered in the Dubai International Financial Center ("DIFC") and licensed and regulated by the Dubai Financial Services Authority ("DFSA") to Professional Clients and Market Counterparties only and should not be relied upon or distributed to Retail Clients. A distribution of the different Citi Research ratings distribution, in percentage terms for Investments in each sector covered is made available on request. Financial products and/or services to which the Materials relate will only be made available to Professional Clients and Market Counterparties. The Product is made available in **United Kingdom** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. This material may relate to investments or services of a person outside of the UK or to other matters which are not regulated by the FSA and further details as to where this may be the case are available upon request in respect of this material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB. The Product is made available in **United States** by Citigroup Global Markets Inc, which is a member of FINRA and registered with the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013. Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Limited, which is regulated by Financial Services Authority. Pursuant to Comissão de Valores Mobiliários Rule 483, Citi is required to disclose whether a Citi related company or business has a commercial relationship with the subject company. Considering that Citi operates multiple businesses in more than 100 countries around the world, it is likely that Citi has a commercial relationship with the subject company.

Many European regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. The policy applicable to Citi Research's Products can be found at https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures.

Compensation of equity research analysts is determined by equity research management and Citigroup's senior management and is not linked to specific transactions or recommendations.

The Product may have been distributed simultaneously, in multiple formats, to the Firm's worldwide institutional and retail customers. The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would not be permitted.

Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt, investors should seek advice from a tax adviser. The Product does not purport to identify the nature of the specific market or other risks associated with a particular transaction. Advice in the Product is general and should not be construed as personal advice given it has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs. Prior to acquiring any financial product, it is the client's responsibility to obtain the relevant offer document for the product and consider it before making a decision as to whether to purchase the product. With the exception of our product that is made available only to Qualified Institutional Buyers (QIBs) and other product that is made available through other distribution channels only to certain categories of clients to satisfy legal or regulatory requirements, Citi Research concurrently disseminates its research via proprietary and non-proprietary electronic distribution platforms. Periodically, individual Citi Research analysts may also opt to circulate research posted on such platforms to one or more clients by email. Such email distribution is discretionary and is done only after the research has been disseminated via the aforementioned distribution channels. Citi Research simultaneously distributes product that is limited to QIBs only through email distribution.

The level and types of services provided by Citi Research analysts to clients may vary depending on various factors such as the client's individual preferences as to the frequency and manner of receiving communications from analysts, the client's risk profile and investment focus and perspective (e.g. market-wide, sector specific, long term, short-term etc.), the size and scope of the overall client relationship with Citi and legal and regulatory constraints. Citi Research product may source data from dataCentral. dataCentral is a Citi Research proprietary database, which includes Citi estimates, data from company reports and feeds from Reuters and Datastream.

© 2013 Citigroup Global Markets Inc. Citi Research is a division of Citigroup Global Markets Inc. Citi and Citi with Arc Design are trademarks and service marks of Citigroup Inc. and its affiliates and are used and registered throughout the world. All rights reserved. Any unauthorized use, duplication, redistribution or disclosure of this report (the "Product"), including, but not limited to, redistribution of the Product by electronic mail, posting of the Product on a website or page, and/or providing to a third party a link to the Product, is prohibited by law and will result in prosecution. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient to any third party. Where included in this report, MSCI sourced

information is the exclusive property of Morgan Stanley Capital International Inc. (MSCI). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, disseminated or used to create any financial products, including any indices. This information is provided on an "as is" basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI, Morgan Stanley Capital International and the MSCI indexes are services marks of MSCI and its affiliates. The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the Firm has not reviewed the linked site. Equally, except to the extent to which the Product refers to website material of the Firm, the Firm takes no responsibility for, and makes no representations or warranties whatsoever as to, the data and information contained therein. Such address or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in anyway form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST
